Cancer therapy developer Oric, whose backers include Memorial Sloan, Taiho and Hartford HealthCare, floated at the top of its range in an expanded IPO.

Oric Pharmaceuticals, a US-based cancer therapy developer backed by corporate investors Taiho, Hartford HealthCare and Memorial Sloan Kettering Cancer Center, went public on Friday in a $120m initial public offering. The IPO consisted of 7.5 million shares priced at the top of its $14 to $16 range. Oric had initially sought to issue 5 million…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.